Ameliorating effect of FK614, a novel nonthiazolidinedione peroxisome proliferator-activated receptor γ agonist, on insulin resistance in Zucker fatty rat

European Journal of Pharmacology

Volumn 519, Issue 1-2, 2005, Pages 182-190

  Minoura, Hideaki ^a   Takeshita, Shigeru ^a   Yamamoto, Tadashi ^a   Mabuchi, Miyuki ^a   Hirosumi, Jiro ^a   Takakura, Shoji ^a   Kawamura, Ikuo ^a   Seki, Jiro ^a   Manda, Toshitaka ^a   Ita, Makoto ^a   Mutoh, Seitaro ^a  

^a ASTELLAS PHARMA INC   (Japan)

Author keywords

FK614; Insulin sensitizer; Nonthiazolidindione; PPAR (peroxisome proliferator activated receptor) ; Zucker fatty rat

Indexed keywords

BIGUANIDE; FK 614; GLUCOSE; INSULIN; METFORMIN; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA AGONIST; PIOGLITAZONE; ROSIGLITAZONE; UNCLASSIFIED DRUG; 2,4 THIAZOLIDINEDIONE DERIVATIVE; 3 (2,4 DICHLOROBENZYL) 2 METHYL N (PENTYLSULFONYL) 3 H BENZIMIDAZOLE 5 CARBOXAMIDE; 3-(2,4-DICHLOROBENZYL)-2-METHYL-N-(PENTYLSULFONYL)-3 H-BENZIMIDAZOLE-5-CARBOXAMIDE; ANTIDIABETIC AGENT; BENZIMIDAZOLE DERIVATIVE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DOSE LIVER FUNCTION RELATION; DRUG MECHANISM; DRUG POTENCY; GLUCOSE BLOOD LEVEL; GLUCOSE TOLERANCE; HYPERINSULINEMIA; INSULIN BLOOD LEVEL; INSULIN RESISTANCE; MALE; NONHUMAN; ORAL GLUCOSE TOLERANCE TEST; PRIORITY JOURNAL; RAT; ANIMAL; BLOOD; COMPARATIVE STUDY; DOSE RESPONSE; DRUG EFFECT; DRUG POTENTIATION; GLUCOSE INTOLERANCE; GLUCOSE TOLERANCE TEST; LIVER; METABOLISM; ORAL DRUG ADMINISTRATION; TIME; ZUCKER RAT;

ADMINISTRATION, ORAL; ANIMALS; BENZIMIDAZOLES; BLOOD GLUCOSE; DOSE-RESPONSE RELATIONSHIP, DRUG; GLUCOSE; GLUCOSE INTOLERANCE; GLUCOSE TOLERANCE TEST; HYPOGLYCEMIC AGENTS; INSULIN; INSULIN RESISTANCE; LIVER; MALE; METFORMIN; PPAR GAMMA; RATS; RATS, ZUCKER; THIAZOLIDINEDIONES; TIME FACTORS;

EID: 27744523803     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejphar.2005.05.042     Document Type: Article

References (21)

1. M. Bajaj, S. Suraamornkul, T. Pratipanawatr, L.J. Hardies, W. Pratipanawatr, L. Glass, E. Cersosimo, Y. Miyazaki, and R.A. DeFronzo Pioglitazone reduces hepatic fat content and augments splanchnic glucose uptake in patients with type 2 diabetes Diabetes 52 2003 1364 1370
2. C.L. Brand, J. Sturis, C.F. Gotfredsen, J. Fleckner, C. Fledelius, B.F. Hansen, B. Andersen, J.-M. Ye, P. Sauerberg, and K. Wassermann Dual PPARα/γ activation provides enhanced improvement of insulin sensitivity and glycemic control in ZDF rats Am. J. Physiol.: Endocrinol. Metab. 284 2003 E841 E854
3. K. Cusi, A. Consoli, and R.A. DeFronzo Metabolic effects of metformin on glucose and lactate metabolism in noninsulin-dependent diabetes mellitus J. Clin. Endocrinol. Metab. 81 1996 4059 4067
4. S.E. Inzucchi, D.G. Maggs, G.R. Spollett, S.L. Page, F.S. Rife, V. Walton, and G.I. Shulman Efficacy and metabolic effects of metformin and troglitazone in type 2 diabetes mellitus N. Engl. J. Med. 338 1998 867 872
5. D.G. Maggs, T.A. Buchanan, C.F. Burant, G. Cline, B. Gumbiner, W.A. Hsueh, S. Inzucchi, D. Kelly, J. Nolan, J.M. Olefsky, K.S. Polonsky, D. Silver, T.R. Valiquett, and G.I. Shulman Metabolic effects of troglitazone monotherapy in type 2 diabetes mellitus: a randomized, double-blind, placebo-controlled trial Ann. Intern. Med. 128 1998 176 185
6. H. Minoura, S. Takeshita, M. Ita, J. Hirosumi, M. Mabuchi, I. Kawamura, S. Nakajima, O. Nakayama, H. Kayakiri, T. Oku, A. Ohkubo-Suzuki, M. Fukagawa, H. Kojo, K. Hanioka, N. Yamasaki, T. Imoto, Y. Kobayashi, and S. Mutoh Pharmacological characteristics of a novel nonthiazolidinedione insulin sensitizer, FK614 Eur. J. Pharmacol. 494 2004 273 281
7. Y. Miyazaki, L. Glass, C. Triplitt, M. Matsuda, K. Cusi, A. Mahankali, L.J. Mandarino, and R.A. DeFronzo Effect of rosiglitazone on glucose and non-esterified fatty acid metabolism in type II diabetic patients Diabetologia 44 2001 2210 2219
8. Y. Miyazaki, A. Mahankali, M. Matsuda, L. Glass, S. Mahankali, E. Ferrannini, K. Cusi, L.J. Mandarino, and R.A. DeFronzo Improved glycemic control and enhanced insulin sensitivity in type 2 diabetic subjects treated with pioglitazone Diabetes Care 24 2001 710 719
9. Y. Miyazaki, A. Mahankali, M. Matsuda, S. Mahankali, J. Hardies, K. Cusi, L.J. Mandarino, and R.A. DeFronzo Effect of pioglitazone on abdominal fat distribution and insulin sensitivity in type 2 diabetic patients J. Clin. Endocrinol. Metab. 87 2002 2784 2791
10. Y. Miyazaki, M. Matsuda, and R.A. DeFronzo Dose-response effect of pioglitazone on insulin sensitivity and insulin secretion in type 2 diabetes Diabetes Care 22 2002 517 523
11. Y. Miyazaki, H. He, L.J. Mandarino, and R.A. DeFronzo Rosiglitazone improves downstream insulin receptor signaling in type 2 diabetic patients Diabetes 52 2003 1943 1950
12. L. Rossetti, R.A. DeFronzo, R. Gherzi, P. Stein, G. Andraghetti, G. Falzetti, G.I. Shulman, E. Klein-Robbenhaar, and R. Cordera Effect of metformin treatment on insulin action in diabetic rats: in vivo and in vitro correlations Metabolism 39 1990 425 435
13. B.M. Spiegelman PPAR-γ. Adipogenic regulator and thiazolidinedione receptor Diabetes 47 1998 507 514
14. R. Steele Influence of glucose loading and of injected insulin on hepatic glucose output Ann. N.Y. Acad. Sci. 82 1959 420 430
15. M. Stumvoll, N. Nurjhan, G. Perriello, G. Dailey, and J.E. Gerich Metabolic effects of metformin in non-insulin-dependent diabetes mellitus N. Engl. J. Med. 333 1995 550 554
16. Y. Sugiyama, Y. Shimomura, and H. Ikeda Effects of pioglitazone on hepatic and peripheral insulin resistance in Wister fatty rats Arzneim.-Forsch. 40 1990 436 440
17. S.L. Suter, J.J. Nolan, P. Wallace, B. Gumbiner, and J.M. Olefsky Metabolic effects of new oral hypoglycemic agent CS-045 in NIDDM subjects Diabetes Care 15 1992 193 203
18. J. Terrettaz, and B. Jeanrenaud In vivo hepatic and peripheral insulin resistance in genetically obese (fa/fa) rats Endocrinology 112 1983 1346 1351
19. M. Tiikkainen, A.-M. Häkkinen, E. Korsheninnikoova, T. Nyman, S. Mäkimattila, and H. Yki-Järvinen Effects of rosiglitazone and metformin on liver fat content, hepatic insulin resistance, insulin clearance, and gene expression in adipose tissue in patients with type 2 diabetes Diabetes 53 2004 2169 2176
20. M. Tominaga, M. Matsumoto, M. Igarashi, H. Eguchi, A. Sekikawa, and H. Sasaki Insulin antibody does not cause insulin resistance during glucose clamping in rats Diabetes Res. Clin. Pract. 18 1992 143 151
21. R. Vettor, N. Zarjevski, I. Cusin, F. Rohner-Jeanrenaud, and B. Jeanrenaud Induction and reversibility of an obesity syndrome by intracerebroventricular neuropeptide Y administration to normal rats Diabetologia 37 1994 1202 1208